Projects

Mf Clearance post-IDA in Samoa

What is the effectiveness of appropriately dosed IDA in clearing microfilariae (Mf) from Mf positive people who (i) reported taking triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) in August 2018, and (ii) did not report recently taking IDA.

This will be investigated by:

  • assessing the baseline (current) Mf presence and density before re/treatment with IDA, against which post-treatment Mf presence and density can be compared
  • assessing the peak plasma concentration levels of ivermectin, DEC and albendazole in treated Mf positive individuals to identify whether the recommended dosages of medications are sufficient for achieving effective plasma concentrations
  • assessing Mf clearance one week following directly observed IDA re/treatment
Countries: Samoa

TAS 3 positive case follow-up

Is there still LF transmission after successful TAS 3?

Countries: Nepal | Nepal

Assessing drug coverage following mass drug administration to monitor the impact of the WHO recommended three-drug regimen of ivermectin, diethylcarbamazine, and albendazole for the elimination of lymphatic filariasis

To validate the reported coverage of the 2018 mass drug administration in American Samoa in order to assess the impact of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) for lymphatic filariasis  on infection prevalence

Countries: American Samoa

Improving Mass Drug Administration After Pre-Transmission Assessment Survey (Pre-TAS) Failure: A Mixed Methods Study in Nepal

This study builds on the methods developed for the operational studies ongoing in Ghana and Burkina Faso. The first two research questions are the same as those earlier studies with two new questions added here- question 3 on triple drug therapy (ivermectin, DEC, albendazole – IDA) and 4 on the use of a new rapid ethnography approach.

  1. What factors are associated with effective (and lower) MDA coverage as defined as availability, accessibility, and acceptability in settings that have repeatedly failed Pre-TAS?
  2. What is the impact of an adapted and tailored intervention package on achieving effective coverage?
  3. What messages and community engagement approaches are needed to ensure the acceptability of IDA triple drug therapy in Nepal?
  4. How does the rapid ethnography approach compare to more traditional qualitative analysis methods in terms of cost, timeliness, and ability to provide required information for programmatic decisions? Can local capacity for use of this approach be built rapidly?
Countries: Nepal

Operational research to develop an M&E study to guide a triple drug stopping decision for lymphatic filariasis in India

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: India

Ov16 AP ELISA comparison in Cameroon

How does the performance of the AP ELISA compare to the Ov16 SD ELISA, when conducted in a country lab?

Countries: Cameroon
Diseases: Onchocerciasis

Operational research to compare the confirmatory mapping tool and xenomonitoring indicator (infectivity rate of L3 of Wuchereria bancrofti) in Monrovia to assess the necessity to implement MDA

What is the most appropriate method to evaluate the presence of W. bancrofti transmission in urban conurbations to establish if MDA is necessary for LF elimination?

Countries: Liberia

Trachomatous Trichiasis Management in Tanzania: Investigation of the productivity of case finding and referral of patients to trichiasis surgery services

One of important pillar of Trachoma elimination as a public health problem is to manage through epilation and surgery trachomatous trichiasis (TT) to reach in endemic district less than 0.1% of TT prevalence or less than 0.2% prevalence in adults of 15 years and older. However, surveys in 3 districts of Tanzania where numbers of TT surgeries were performed showed an unexpected higher prevalence despite intervention. This mixed methods study will help to address the main question as to why trachoma impact surveys demonstrating unexpectedly high TT prevalence in communities where TT surgical intervention is ongoing and how could this intervention/burden gap be addressed? The aim is to look at the case finding techniques effectiveness in all the communities and factors that affect TT referral and quality surgical services.

Countries: Tanzania | Tanzania | Tanzania
Diseases: Trachoma

Pages